Kornimate/medical-research-clean huggingface dataset:
resilience intervention for health professionals covid-19

Conditions: Mental Health Wellness 1

Summary: in the fight against the coronavirus (covid-19) pandemic, health personnel, especially nursing staff, have been facing enormous pressure, including a high risk of infection and inadequate protection against contamination, overwork, frustration, discrimination, isolation, lack of contact with their families and exhaustion. therefore, the world health organization (who) has requested particular interventions to promote emotional well-being in health workers exposed to covid-19, which must be implemented immediately, especially those aimed at women and nursing staff. . psychological support services, including counseling or intervention via phone, internet, and apps, have been widely deployed by local and national mental health institutions in response to the covid-19 outbreak. complementing these efforts, the present study seeks, through mind-body medicine strategies, to promote resilience among nurses exposed to covid-19 in critical phases. a multidisciplinary team of expert volunteers designed the intervention in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified qi gong, and yoga instructors) and is made up of 3 components main: "micropractices," cohesion and support groups, which will be implemented for 12 weeks in health personnel. this intervention responds to the international call to promote health personnel's physical and emotional health during the covid-19 pandemic, offering an opportunity to accompany them during this time and mitigate the effects on health in the short and long term.


Eligibility criteria:
inclusion criteria: * signed informed consent exclusion criteria: * lack of signature in the informed consent

Keywords: mindfulness resilience covid-19 nurses
the role of parathyroid hormone (pth) in low bone mass in anorexia nervosa

Conditions: Anorexia Nervosa; Osteoporosis

Summary: decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa, or disordered eating. women with decreased bone strength are more likely to suffer broken bones than women with normal bone strength. we are investigating whether a hormone that is naturally produced by the human body -- parathyroid hormone (pth) -- can help strengthen the bones of women with anorexia nervosa.

anorexia nervosa affects 0.5-1% of college-age women in the us and is associated with a number of significant medical conditions including bone loss. a majority of women with anorexia nervosa have bone loss and 50% have bone mineral density measurements greater than 2 standard deviations below normative means. bone loss in anorexia nervosa is characterized by a decrease in bone formation, therefore therapy with an anabolic agent may be an effective treatment approach. in a randomized, single-blinded, placebo-controlled trial, we will study the effects of parathyroid hormone on low bone mass in anorexia nervosa, specifically looking at the effects of parathyroid hormone on bone mineral density (primary outcome).

Eligibility criteria:
inclusion criteria: * anorexia nervosa * women, age 30-70 years * osteoporosis or history of clinical fractures (spine, wrist, hip or ribs) exclusion criteria: * diseases known to affect bone metabolism * hyperparathyroidism * medications known to affect bone metabolism in last 12 weeks (or bisphosphonate use in last 1 year) * pregnant and/or breastfeeding * diabetes mellitus * history of malignancy involving or affecting the bone, any active malignancy, and/or radiation therapy to the bone * fractures of a bone other than a finger or toe in last 1 year

Keywords: anorexia nervosa disordered eating osteoporosis parathyroid hormone bone
risk taking and decision-making in cluster headache patients

Conditions: Cluster Headache

Summary: since there is conflicting and insufficient data regarding ch personality and addictive behaviour, the investigators will investigate risk- and reward seeking behaviour in people with cluster headache. if an increased tendency towards this behaviour is shown, it will add to the clinical knowledge of cluster headache and possible lead to insights in a common biological susceptibility.

cluster headache is a severe primary headache disorder. in clinical anecdotes, people with cluster headache frequently report use of tobacco and illicit drugs. furthermore, addictive behaviours and tattoos are considered to be more common in people with cluster headache than in the general population. the causality of these associations remains unclear. a common biological susceptibility has been proposed, predisposing people to both addictive behaviour and cluster headache. on the other hand, a role of illicit drug exposure in cluster headache pathophysiology has been suggested. the increased use of tobacco and illicit drugs could also reflect attempts to treat cluster headache attacks. in this explorative study the investigators will assess both subjective and objective measures reflecting addictive behaviour and risk- and reward seeking in cluster headache. this will add to the clinical knowledge of cluster headache and possible lead to insights in a common biological susceptibility.

Eligibility criteria:
inclusion criteria: * age 18-64 years * normal or corrected vision with acuity up to 20/60 * presence of episodic (n=35) or chronic (n=35) cluster headache or migraine with or without arua (n=35), diagnosed according to the international classification of headache disorders criteria, 3rd edition (ichd-3, 3.1.1) exclusion criteria: * diagnosis of uncorrected visual problems (myopia/presbiopia, peripheral vision problems or legal blindness) * current diagnosis of generalized anxiety disorder, depression or other psychiatric illness * other acute, unstable medical conditions or serious chronic diagnoses
a multi-center randomized controlled trial of intraportal chemotherapy combined with adjuvant chemotherapy (mfolfox6) for stage ii and iii colon cancer

Conditions: Colorectal Cancer; Metastasis

Summary: to investigate whether intraoperative intraportal chemotherapy combined with adjuvant chemotherapy as treatment could improve disease-free survival (dfs) in patients with curative colorectal cancer resection compared with adjuvant chemotherapy alone. this is a prospective, blind (doctors who done outcome measures were masked), multi-center, 2-arm randomized controlled trial.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and ≤ 75 years; 2. primary tumor has undergone histologically confirmed colon adenocarcinoma; colon cancer was defined by the presence of the inferior pole of the tumor above the peritoneal reflection (at least 15 cm from the anal margin). 3. together with clinical or radiological evidence of stage ii (t3-4, n0, m0) or stage iii (t1-4, n1-2, m0) disease (according to the 2007 revision of the international union against cancer tnm staging system) 4. performance status (ecog) 0\~1 5. adequate hematological function: neutrophils≥1.5 x109/l and platelet count≥100 x109/l; hb ≥9g/dl (within 1 week prior to randomization) 6. adequate hepatic and renal function: serum bilirubin≤1.5 x upper limit of normal (uln), alkaline phosphatase ≤5x uln, and serum transaminase (either ast or alt) ≤ 5 x uln(within 1 week prior to randomization); 7. written informed consent for participation in the trial. exclusion criteria: 1. previous exposure to prior cancer therapy (chemotherapy, radiotherapy or intervention therapy) for colon cancer. 2. patients with known hypersensitivity reactions to any of the components of the study treatments. 3. other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix 4. pregnancy (absence confirmed by serum/urine β-hcg) or breast-feeding 5. known drug abuse/ alcohol abuse 6. legal incapacity or limited legal capacity 7. pre-existing peripheral neuropathy.

Keywords: adjuvant chemotherapy intraportal chemotherapy prevention
envafolimab monotherapy or envafolimab + capeox as neoadjuvant therapy for locally advanced colorectal cancer

Conditions: Colon Cancer; Neoadjuvant Therapy; Immunotherapy

Summary: there exists substantial evidence suggesting that patients diagnosed with msi-h/dmmr colorectal cancer can derive benefits from immunotherapy in the management of advanced colorectal cancer. in cases of locally advanced colorectal cancer exhibiting microsatellite instability (dmmr/msi-h), patients exhibit low responsiveness to neoadjuvant chemotherapy, resulting in minimal rates of complete tumor remission and downstaging. nevertheless, initial exploratory studies, characterized by modest sample sizes, reveal a favorable therapeutic effect of neoadjuvant immunotherapy in this particular patient population. envafolimab monoclonal antibody, the first pd-l1 antibody developed and manufactured in china, possesses noteworthy practical and societal value in the context of exploratory clinical research on neoadjuvant immunotherapy for locally advanced msi-h/dmmr colorectal cancer patients. the objective of this study is to evaluate the safety and efficacy of envafolimab monoclonal antibody (pd-l1) as neoadjuvant therapy for locally advanced msi-h/dmmr colorectal cancer through a prospective, multi-cohort phase ii clinical trial. additionally, this study aims to investigate the effectiveness and safety of envafolimab monoclonal antibody in combination with capeox as a neoadjuvant treatment regimen for locally advanced pmmr colorectal cancer.


Eligibility criteria:
inclusion criteria: * pathological confirmed rectal cancer * clinical stage t3-4 or t any n1 * with or without mrf positivity, with or without emvi positivity * r0 resection is estimated * age ranged from 18 to 70 exclusion criteria: * clinical stage t1-2 n0 * distance metastasis * multiple primary tumor * cachexy
does micro-albuminuria is a predictive factor for cognitive impairment in persons living with hiv (plhiv) who achieve cart-sustained immunovirological control ?

Conditions: HIV

Summary: chronic kidney disease (ckd), frequent in plhiv, is a risk factor for cognitive impairment. micro-albuminuria is an early manifestation of ckd and a marker of vascular risk, notably affecting the small vessels. in the older general population microalbuminuria is associated with greater annual cognitive decline and has been proposed as an easily and inexpensive measured marker predicting future cognitive function decline. ageing of the plh leads to an increase of cognitive disorders and chronic renal failure incidence and could imply a common underlying mechanism affecting the renal and cerebral microvasculature. in this setting the investigators undertake this prospective, cross-sectional, case-control study to determine whether the presence of a microalbuminuria at least 5 years ago in plhs with sustained good combination antiretroviral therapy (cart)-controlled immunovirological parameters could be a marker predicting future cognitive impairment. they chose plhs infected for at least 5 years and with cart-sustained immunovirological control for at least 1 year.


Eligibility criteria:
inclusion criteria: * known hiv infection for at least 5 years * undetectable viral load under antiretroviral (arv) treatment for at least 1 year, regardless of the type of arv * number of cd4 ≥ 350, regardless of the cd4 nadir * unopposed to participate to the study for cases - micro-albuminuria defined by microalbuminuria / creatinuria between 3 and 30 mg/mmol for controls, matched for age +/- 5 years - absence of microalbuminuria defined by microalbuminuria / creatinuria \<3 mg/mmol exclusion criteria * known neurological disease, active or former * active and regular use of drugs * active chronic alcoholism * diabetes with known complications * renal failure with glomerular filtration rate \<15 ml / min * micro-albuminuria / creatinuria\> 30 mg / mmol * hivan * unbalanced arterial hypertension * patient did not have dosing glucose and lipid levels in over a year * unaffiliated patient (or copyright holder) to a social security scheme * people enjoying a measure of legal protection pregnant or breastfeeding secondary exclusion criteria - neurological disease found during the assessment.

Keywords: cognitive impairment hiv microalbuminuria chronic kidney disease
clinical outcomes from nocd treatment of obsessive-compulsive disorder using exposure and response prevention

Conditions: Obsessive-Compulsive Disorder

Summary: this is a naturalistic, observational study of individuals with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy, augmented with between-session support with text messaging and an online community forum.


Eligibility criteria:
inclusion criteria: * obsessive-compulsive disorder exclusion criteria: * none

Keywords: exposure and response prevention digital behavioral health remote treatment video therapy
function benefits of a myoelectric elbow-wrist-hand orthosis

Conditions: Cerebrovascular Accidents

Summary: the objective of this study is to evaluate the functional benefits of a myoelectric elbow-wrist-hand orthosis for persons with upper limb paralysis caused by a cerebrovascular accident (cva).

the objective of this study is to evaluate the functional gains provided by a myoelectric elbow-wrist-hand orthosis for cva patients with hemiparesis. the subjects will be fit with the device, provided general training in the operation of the emg-controlled technology, and then guided through a series of standard clinical outcome measures used routinely as part of stroke rehabilitation medicine. the outcome measures employed in this study include the fugl-meyer assessment, the box and blocks test, and a battery of common functional tasks and activities. these outcome measures will allow the researchers to approximate the changes in the subjects' ability to successfully perform functional tasks with and without the myopro device.

Eligibility criteria:
inclusion criteria: * adults over 18 years. * upper limb impairment caused by any stroke (cva) * minimum of trace mmt (1/5) in biceps and/or triceps * full passive range of motion in elbow, forearm, wrist, and hand * active shoulder flexion of at least 30 degrees of shoulder abduction of at least 20 degrees * score of at least 20 on the mini mental status examination. * ability to read and comprehend the english language. * ability to generate consistent, detectable emg signal from the upper arm and forearm sensor sites with wrist in neutral or flexed positions. exclusion criteria: * fixed upper limb contractures on affected side. * subjects with severe spasticity or tone (defined as 3 or more on the modified ashworth scale). * inability to follow three step directions. * severe shoulder subluxation, pain or shoulder dislocation. * passive shoulder range of motion less than 45 degrees in flexion and abduction. * pain or hypersensitivity in the arm(s)
precision medicine for every child with cancer

Conditions: Childhood Cancer; Childhood Solid Tumor; Childhood Brain Tumor; Childhood Leukemia; Refractory Cancer; Relapsed Cancer

Summary: to improve outcomes for childhood cancer patients through the implementation of precision medicine.

through the pilot target and national prism trials the feasibility and benefits of using comprehensive molecular profiling and preclinical drug testing in real time for high-risk (hr) patients has been demonstrated. however, the role of precision medicine, especially in facilitating diagnosis and risk stratification in non-hr childhood cancers has not been studied. integrative tumor-germline whole genome sequencing (wgs) analysis has the potential to advance our understanding of cancer predisposition. in this study, the zero platform will be extended to all children with cancer in australia and new zealand, evaluating the benefits of precision medicine in different childhood cancer types and risk groups.

Eligibility criteria:
inclusion criteria: 1. age \< 18 years note: individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the study chair or their delegate. 2. life expectancy \>6 weeks at time of enrolment 3. consent i. signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged \<18 years. ii. separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.

Keywords: children precision medicine personalised medicine molecular profiling pediatric paediatric
effect of delta-9-tetrahydrocannabinol on the prevention of chronic pain in patients with acute crps (etic-study)

Conditions: Complex Regional Pain Syndromes; CRPS

Summary: the purpose of this study is to determine whether application of low dose delta9-tetrahydrocannabinol can prevent the development of chronic pain in patients with acute crps.

recent animal data suggest that the endocannabinoid system is a promising target in the prevention of chronic pain. it has been shown that the endocannabinoid system modifies excitatory and inhibitory currents in structures involved in the development of chronic pain such as the amygdala. crps is a neuropathic pain condition, which is known to become chronic in a significant percentage. the study compares the effect of low dose delta9-tetrahydrocannabinol (90 days) and placebo in acute crps. all patients will receive a standard treatment consisting of drug therapy and physiotherapy.

Eligibility criteria:
inclusion criteria: * patients with clinical diagnosis of acute crps (time from inciting event less than 16 weeks) of the upper extremity * no risk of dependency in a psychological assessment exclusion criteria: * history of alcohol or drug abuse * cardiac arrhythmias * acute or chronic renal failure * asa physical status classification iii or higher * psychiatric disorders * pregnancy and breast feeding

Keywords: thc crps pain complex regional pain syndrome neuropathic pain chronic prevention
incidence of infection after total knee arthroplasty using an erythromycin and colistin loaded cement or a standard cement

Conditions: Infection After Primary Total Knee Arthroplasty

Summary: prospective randomized study in cemented primary total knee arthroplasty. in one group the cement used was standard cement, without any antibiotics and in the other group the cement used was loaded with 0.5 g of erythromycin and 3 million units of colistin in 40 g of cement. in all cases intravenous antibiotics prophylaxis against infection was used. in both groups the cement was mechanically mixed in a vacuum. one deep drain tube was placed for 24 hours in all cases. the main variable was the presence of infection according to the center of disease control criteria with a minimum of 12 months follow-up.


Eligibility criteria:
inclusion criteria: * primary total knee replacement. both genders. no age limits. exclusion criteria: * allergy to erythromycin or colistin. previous infection in the knee.
stability of implants with different surface treatment: randomized clinical trial

Conditions: Edentulous Jaws Partially

Summary: objectives: to compare the stability of implant surface treated by dual acid etching (porous)and implants with anodized surface (vulcano) over a period of 16 weeks after installation. methods: it will be a clinical study with individuals with missing teeth requiring rehabilitation with dental implants in the maxilla and that fulfill the study inclusion criteria. the research sites will be randomized into two groups: the control group patient's sites receive implant surface treated by dual acid (ar torque porous, connection implant systems, aruja, brazil) and in the test group implants with anodized surface (ar torque vulcano-actives, connection implant systems, aruja, brazil). the evaluation of the stability of the implants will be made over 16 weeks, through resonance frequency analysis with osstell (integration diagnostics ab, gothenburg, sweden). data will be analyzed using descriptive statistics and comparative.


Eligibility criteria:
inclusion criteria: * patients who have missing teeth in the maxilla, * over 30 years old and under 60 years old, * the implant sites with at least 3 months of healing after extraction, * the implant sites with width and length to installation of an implant of 4 mm x 10 mm. exclusion criteria: * patients who experience any of the following conditions: * general contraindications for surgical procedures, * uncontrolled diabetes, * severe bruxism or clenching, * pregnant and lactating women, * active periodontal disease, * smoker and user of alcohol or drugs.

Keywords: dental implant stability dental implant surface treatment resonance frequence analysis
assessment of strength outcomes after use of the primusrs for specificity of training in a cardiac rehabilitation setting

Conditions: Coronary Artery Disease; Valve Disease, Heart

Summary: the purpose of this study is to determine if performed force measurements yield a different recommended weight lifted during the sternotomy healing process than the traditional gold standard of 5 pounds. a secondary endpoint data obtained will be scores from the pre and post-activity questionnaires.

in a prospective study involving 130 cardiac rehabilitation patients muscular strength will be measured with a force dynamometer (primus) on six commonly performed activities. during the first session of cardiac rehabilitation, each subject's date of birth, height, and weight will be recorded. to ensure safety, cardiovascular nurse specialists and exercise physiologists will monitor the patients for hypertension (blood pressure \>240/110 mm hg), arrhythmias, angina, dizziness, pain, shortness of breath, and perceived exertion. the subjects will be asked to complete a pre-activity confidence survey. on the second day of cardiac rehabilitation, a clinical exercise specialist will the primus equipment to obtain force measurements on the six activities including: rising from a bed, rising from a chair, opening a door, lifting an object from the floor and/or placing an object overhead. following the performance of the activities, the patients will be asked to complete a post-activity confidence survey.

Eligibility criteria:
inclusion criteria: * cabg through median sternotomy * valve repair or replacement through median sternotomy * any ethic of socio-economic status exclusion criteria: * refusal to participate * sternal dehiscence * permanent pacemaker * permanent defibrillator * unstable angina * history of heart transplant * history of hernia * history of aneurysm * physical disability that limits resistance training * uncontrolled hypertension (systolic 160 mmhg or diastolic \> 100 mmhg) * symptomatic dysrhythmias * history of aortic dissection

Keywords: coronary artery bypass graft valve replacement valve repair median sternotomy
ultrasonographic evaluation of the diaphragm during nhf versus niv use in respiratory failure

Conditions: Diaphragm Issues; Respiratory Failure With Hypoxia; Respiratory Failure With Hypercapnia; Non-invasive Mechanical Ventilation

Summary: this study will describe influence of nhf or niv to different ultrasonographic parameters of the diaphragm. therefor subjects will be randomized to the sequence nhf and than niv or niv and than nhf. in all subjects same parameters will be evaluated.


Eligibility criteria:
inclusion criteria: * acute or chronic respiratory failure, hyperemic or hypercapnic * age \> 18 yrs * written consent exclusion criteria: * critical disease (intubation, heart failure, lung edema,..) * no compliance * metabolic acidosis